Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Gastrointestinal Stromal Tumors 3 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma 1 Pathologic Complete Response 1 Ovarian Neoplasms 1 Neurofibrosarcoma 1 Neoplasms 1 Melanoma 1 Hemangiosarcoma 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Doxorubicin 17 Ifosfamide 12 Radiotherapy 8 pazopanib 5 selinexor 4 pembrolizumab 4 Filgrastim 4 pegfilgrastim 3 Sirolimus 3 Nivolumab 3 Magnetic Resonance Spectroscopy 3 Imatinib Mesylate 3 Etoposide 3 AZD 6244 3 fludarabine phosphate 2 brostallicin 2 X-Rays 2 Trabectedin 2 Specimen Handling 2 Sorafenib 2 Radiation Dose Hypofractionation 2 Radiation 2 Diathermy 2 Chemotherapy, Adjuvant 2 Biopsy 2 thymoglobulin 1 temsirolimus 1 tazemetostat 1 sotigalimab 1 sapanisertib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neurofibrosarcoma × pexidartinib × Sarcoma × Clear all

NCT02584647 2025-03-21

PLX3397

Columbia University

Phase 1/2 Terminated

39 enrolled 13 charts

Sarcoma, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡